170 related articles for article (PubMed ID: 26753613)
1. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
[TBL] [Abstract][Full Text] [Related]
2. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
3. Context-Dependent Impact of RAS Oncogene Expression on Cellular Reprogramming to Pluripotency.
Ferreirós A; Pedrosa P; Da Silva-Álvarez S; Triana-Martínez F; Vilas JM; Picallos-Rabina P; González P; Gómez M; Li H; García-Caballero T; González-Barcia M; Vidal A; Collado M
Stem Cell Reports; 2019 May; 12(5):1099-1112. PubMed ID: 31056476
[TBL] [Abstract][Full Text] [Related]
4. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
Granados K; Poelchen J; Novak D; Utikal J
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
[TBL] [Abstract][Full Text] [Related]
5. [The netrin-1 cue regulates somatic cell reprogramming to pluripotency].
Mehlen P; Lavial F
Med Sci (Paris); 2016 Mar; 32(3):241-4. PubMed ID: 27011240
[No Abstract] [Full Text] [Related]
6. Common Telomere Changes during In Vivo Reprogramming and Early Stages of Tumorigenesis.
Marión RM; López de Silanes I; Mosteiro L; Gamache B; Abad M; Guerra C; Megías D; Serrano M; Blasco MA
Stem Cell Reports; 2017 Feb; 8(2):460-475. PubMed ID: 28162998
[TBL] [Abstract][Full Text] [Related]
7. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
8. Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.
Olmez I; Shen W; McDonald H; Ozpolat B
J Cell Mol Med; 2015 Jun; 19(6):1262-72. PubMed ID: 25787115
[TBL] [Abstract][Full Text] [Related]
9. Concise review: dedifferentiation meets cancer development: proof of concept for epigenetic cancer.
Yamada Y; Haga H; Yamada Y
Stem Cells Transl Med; 2014 Oct; 3(10):1182-7. PubMed ID: 25122691
[TBL] [Abstract][Full Text] [Related]
10. Tumoral reprogramming: Plasticity takes a walk on the wild side.
Campos-Sánchez E; Cobaleda C
Biochim Biophys Acta; 2015 Apr; 1849(4):436-47. PubMed ID: 25038581
[TBL] [Abstract][Full Text] [Related]
11. The dualistic origin of human tumors.
Liu J
Semin Cancer Biol; 2018 Dec; 53():1-16. PubMed ID: 30040989
[TBL] [Abstract][Full Text] [Related]
12. Activation of pluripotency genes by a nanotube-mediated protein delivery system.
Cho SJ; Choi HW; Cho J; Jung S; Seo HG; Do JT
Mol Reprod Dev; 2013 Dec; 80(12):1000-8. PubMed ID: 24038603
[TBL] [Abstract][Full Text] [Related]
13. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Yamada Y; Yamada Y
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
[TBL] [Abstract][Full Text] [Related]
14. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Verfaillie A; Imrichova H; Atak ZK; Dewaele M; Rambow F; Hulselmans G; Christiaens V; Svetlichnyy D; Luciani F; Van den Mooter L; Claerhout S; Fiers M; Journe F; Ghanem GE; Herrmann C; Halder G; Marine JC; Aerts S
Nat Commun; 2015 Apr; 6():6683. PubMed ID: 25865119
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming supports the invasive phenotype in malignant melanoma.
Bettum IJ; Gorad SS; Barkovskaya A; Pettersen S; Moestue SA; Vasiliauskaite K; Tenstad E; Øyjord T; Risa Ø; Nygaard V; Mælandsmo GM; Prasmickaite L
Cancer Lett; 2015 Sep; 366(1):71-83. PubMed ID: 26095603
[TBL] [Abstract][Full Text] [Related]
16. A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion.
Takeuchi T; Adachi Y; Sonobe H; Furihata M; Ohtsuki Y
Oncogene; 2006 Nov; 25(53):7059-69. PubMed ID: 16715130
[TBL] [Abstract][Full Text] [Related]
17. Linking Pluripotency Reprogramming and Cancer.
Iglesias JM; Gumuzio J; Martin AG
Stem Cells Transl Med; 2017 Feb; 6(2):335-339. PubMed ID: 28191771
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.
Bai J; Zhang Z; Li X; Liu H
Cancer Biomark; 2015; 15(5):599-608. PubMed ID: 26406949
[TBL] [Abstract][Full Text] [Related]
19. Single-gene transgenic mouse strains for reprogramming adult somatic cells.
Carey BW; Markoulaki S; Beard C; Hanna J; Jaenisch R
Nat Methods; 2010 Jan; 7(1):56-9. PubMed ID: 20010831
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
Yilmazer A; de Lázaro I; Taheri H
Cancer Lett; 2015 Dec; 369(1):1-8. PubMed ID: 26276716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
